Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Drug repurposing refers to the application of existing drugs to new therapeutic indications. As phenotypic indicators of human drug response, drug side effects may provide direct signals and unique opportunities for drug repurposing.

Related collections

Most cited references 63

Record: found
Abstract: found
Article: found

Is Open Access

Data Mining of the Public Version of the FDA Adverse Event Reporting System

Toshiyuki Sakaeda, Akiko Tamon, Kaori Kadoyama … (2013)

The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, formerly AERS) is a database that contains information on adverse event and medication error reports submitted to the FDA. Besides those from manufacturers, reports can be submitted from health care professionals and the public. The original system was started in 1969, but since the last major revision in 1997, reporting has markedly increased. Data mining algorithms have been developed for the quantitative detection of signals from such a large database, where a signal means a statistical association between a drug and an adverse event or a drug-associated adverse event, including the proportional reporting ratio (PRR), the reporting odds ratio (ROR), the information component (IC), and the empirical Bayes geometric mean (EBGM). A survey of our previous reports suggested that the ROR provided the highest number of signals, and the EBGM the lowest. Additionally, an analysis of warfarin-, aspirin- and clopidogrel-associated adverse events suggested that all EBGM-based signals were included in the PRR-based signals, and also in the IC- or ROR-based ones, and that the PRR- and IC-based signals were in the ROR-based ones. In this article, the latest information on this area is summarized for future pharmacoepidemiological studies and/or pharmacovigilance analyses.

0 comments Cited 212 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey.

Steven D. Glaser, W B Kowalski, P Stang … (2004)

The current epidemiologic data on hyperhidrosis are scarce and insufficient to provide precise prevalence or impact estimates. We sought to estimate the prevalence of hyperhidrosis in the US population and assess the impact of sweating on those affected by axillary hyperhidrosis. A nationally representative sample of 150,000 households was screened by mailed survey for hyperhidrosis and projected to the US population based on US census data. Ascertainment of hyperhidrosis was based on a question that asked whether participants experienced excessive or abnormal/unusual sweating. The prevalence of hyperhidrosis in the survey sample was 2.9% (6800 individuals). The projected prevalence of hyperhidrosis in the United States is 2.8% (7.8 million individuals), and 50.8% of this population (4.0 million individuals) reported that they have axillary hyperhidrosis (1.4% of the US population). Only 38% had discussed their sweating with a health care professional. Approximately one third of individuals with axillary hyperhidrosis (0.5% of the US population or 1.3 million individuals) reported that their sweating is barely tolerable and frequently interferes, or is intolerable and always interferes, with daily activities. Hyperhidrosis affects a much larger proportion of the US population than previously reported. More than half of these individuals have axillary hyperhidrosis, in which sweating can result in occupational, emotional, psychological, social, and physical impairment.

0 comments Cited 122 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: found

Prevalence and Disease Burden of Hyperhidrosis in the Adult Population

M. Augustin, M.A. Radtke, K Herberger … (2013)

Background: Although hyperhidrosis is a common and burdensome condition, little is known about the population-based prevalence. Objective: To evaluate the epidemiology, disease burden and medical care of hyperhidrosis in German adults. Methods: Employees of fifty-two companies underwent skin screenings and interviews including hyperhidrosis questions. Results: 14,336 individuals were investigated (36% women, mean age 42 years) of whom 2,340 (16.3%) reported hyperhidrosis, including 869 (6.1%) with frequent or continuous disturbing sweating. 28% showed focal hyperhidrosis, whilst 68% had a generalized condition. Predictors of hyperhidrosis were male gender and concomitant drug medication. Moreover, persons with psoriasis and with metabolic comorbidity were at increased risk. Only 27% of those with focal hyperhidrosis had consulted a physician, and only 28% used prescribed medication or self-medication. Conclusion: Hyperhidrosis is a frequent skin condition predicted by medical and personal factors. In spite of the disease burden, few individuals utilize medical care. Affected individuals should be encouraged to refer to a dermatologist.

0 comments Cited 35 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (iso-abbrev): Eur J Med Res

Title: European journal of medical research

Publisher: Springer Science and Business Media LLC

ISSN (Electronic): 2047-783X

ISSN (Print): 0949-2321

Publication date (Electronic): Feb 24 2023

Volume: 28

Issue: 1

Affiliations

[1 ] Department of Pharmacy, Peking University People's Hospital, Beijing, China.

[2 ] Department of Thoracic Surgery, Peking University People's Hospital, Beijing, China. liuyanguo@pkuph.edu.cn.

[3 ] Department of Thoracic Surgery, Peking University People's Hospital, Beijing, China.

[4 ] Department of Pharmaceutical Analysis, School of Pharmacy, Peking University, Beijing, China.

[5 ] Department of Pharmacy, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. Zhaobin@pumch.cn.

[6 ] Department of Pharmacy, Peking University People's Hospital, Beijing, China. huanglin@pkuph.edu.cn.